EN DE
Watch Biosolution Co.Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Biosolution Co.Ltd (086820) fair value: what the stock is really worth

As of Oct 28, 2026: fair value (intrinsic value) of Biosolution Co.Ltd stock KRW 653, price KRW 5,590, upside -88.3%, quality 50 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value 30%+ above price?No
  2. Quality 50+?Yes
  3. In an uptrend?No
  4. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7086820008

BC Biosolution Co.Ltd logo Thin data Oct 28, 2026

Biosolution Co.Ltd

086820 · KQ

Weakest SetupStrongly overvalued and low quality.

Our calculation puts a fair price 88% below what the stock costs today.

Quality 50/100
Expensive Growth (revenue 5y +14.4 %/yr in KRW)
Thin margins · 5.0% net margin (TTM)
Mixed vs. peers (5/9)
Fair value 653.28 KRW · Strongly overvalued (−88.3%)
Negative free cash flow
Narrow moat 18/100 · thin data
Thin data
Structural break
Watch Biosolution Co.Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

12,950 KRW 3,167 KRW Fair Value 653.28 KRW Jun 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year. As of Oct 28, 2026.

How to read this chart

60‑month range 3,167 KRW – 12,950 KRW · fair‑value band 545.08 KRW – 653.28 KRW · the 5,590 KRW price screens above the 653.28 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Oct 28, 2026.

Follow Biosolution Co.Ltd in your weekly email

Every Wednesday you see whether Biosolution Co.Ltd is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Bio Solution Co.,Ltd. develops, manufactures, and sells cell therapy products worldwide.

Show moreShow less

The company offers CartiLife, an autologous chondrocyte cell-based therapy for the restoration of symptomatic and structural complications caused by articular cartilage defects; KeraHeal-Allo, a thermosensitive hydrogel-type allogenic keratinocyte cell-therapy product to promote re-epithelialization of deep 2nd-degree burn wounds; and KeraHeal, an autologous spray-type keratinocyte cell-based therapy for skin wounds.

It also provides reconstructed human micro-tissue models comprising KeraSkin, an epidermis model; KeraSkin-FT, a full-thickness skin model; KeraSkin-M, a pigmented skin model; corneal models; SoluAirway, a airway mucosa model; SoluOral, an oral mucosa model; SoluDPNeuron, a dopaminergic neuron model; SoluDANeuron, an islet model; and SoluLiver, a liver model.

In addition, the company provides human-derived primary cell cultures and primary cells for in vitro research; bio advanced materials; and cosmetics raw materials. The company was formerly known as MCTT Bio Co., Ltd. and changed its name to Bio Solution Co.,Ltd. in January 2016.

Bio Solution Co.,Ltd. was founded in 2000 and is headquartered in Seoul, South Korea.

Stock analysis

Biosolution Co.Ltd (086820) currently trades at 5,590 KRW, while our model-based Fair Value estimate is 653.28 KRW, 88.3% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of 2,617 KRW per share, and 0 of the 10 models we run sit above the 5,590 KRW price.

Bear case: the Earnings-Based group reads lowest at 175.43 KRW, and 10 of the 10 models stay below the price. Data coverage for this calculation is low.

Scenario range: 545.08 KRW (bear) to 653.28 KRW (bull), the price of 5,590 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 50/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Biosolution Co.Ltd reported revenue of 15.2B KRW in FY2025 versus 11.8B KRW in FY2021, a compound +6.5%/yr. Reported net income was 273M KRW in FY2025.

Key figures

Market cap 144B KRW (≈ $108M) Micro · P/S ratio 9.94 · Net margin 5.0% · Return on equity 2.5% · Return on assets (EBIT) −6.9% · Operating margin −10.3% · Revenue (TTM) 17.4B KRW · Revenue growth (YoY) +50.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 18 out of 100 (low confidence).

What moves the price

The share trades about 57% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 3% fair-value upside, at −88%, 086820 screens richer than that median.

Fair Value models

The price assumes far more growth than our models allow for, so the models scatter widely (175.43 KRW to 4,906 KRW). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear 545.08 KRW Fair Value 653.28 KRW Bull 653.28 KRW
Price 5,590 KRW · Upside -88.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Owner Earnings 1,684 KRW 2,617 KRW 4,089 KRW 73
Residual Income 741.79 KRW 653.28 KRW 602.81 KRW 71
Growth-Adj P/E 182.65 KRW 260.94 KRW 339.22 KRW 67
All 10 models by family
DCF Models
Owner Earnings 1,684 KRW 2,617 KRW 4,089 KRW 73
Earnings-Based
Graham-Dodd 72.04 KRW 431.11 KRW 600.78 KRW 63
Lynch FV 122.80 KRW 175.43 KRW 228.06 KRW 61
PEG = 1.0 122.80 KRW 175.43 KRW 228.06 KRW 57
Multiples
P/E Multiple 174.79 KRW 233.06 KRW 291.32 KRW 63
P/S Multiple 135.07 KRW 180.09 KRW 225.11 KRW 58
P/B Multiple 3,679 KRW 4,906 KRW 6,132 KRW 55
Asset-Based
NCAV (Graham) 545.08 KRW 730.41 KRW 1,090 KRW 51
Economic Profit
Residual Income 741.79 KRW 653.28 KRW 602.81 KRW 71
Growth Earnings
Growth-Adj P/E 182.65 KRW 260.94 KRW 339.22 KRW 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 50/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 18
How much profit the company makes from its sales and capital
Quality Growth 78
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 54
Debt, balance sheet and risk of trouble
Investment 95
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Momentum 18
Price trend of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 80
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 58/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+17.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.4%
Start year 2020 (pandemic). Over 10 years: +21.5% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−43.0% (2020) → −28.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed

086820 screens overvalued: fair value 88% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Biosolution Co.Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 597 stocks

Beats the industry median on 5/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 50 · Above median
Fair Value upside −88.3% · Bottom 25%
Profitability
Return on equity (12 months) 2.5% · Above median
Return on assets 0.4% · Above median
Net margin (12 months) 5.0% · Above median
Operating margin (12 months) −10.3% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 50.1% · Top 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 4.51× · Priciest 25%
P/S (12 months) 8.29× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)10 · sector 0
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 24

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $816.10 $1,275 +56% vs 086820
Vertex Pharmaceuticals Incorporated VRTX $517.49 $569.24 +10% vs 086820
Samsung Biologics Co 207940 1,374,000 KRW 1,511,400 KRW +10% vs 086820
WuXi Biologics (Cayman) Inc 2269 HK$45.80 HK$50.38 +10% vs 086820
argenx SE ARGX $882.48 $908.40 +3% vs 086820
Alnylam Pharmaceuticals, Inc ALNY $227.66 $217.88 −4% vs 086820
CSL Limited CSL A$196.78 A$178.75 −9% vs 086820
BeOne Medicines AG ONC $370.87 $254.12 −31% vs 086820
Celltrion, Inc 068270 188,600 KRW 74,944 KRW −60% vs 086820
Royalty Pharma plc RPRX $64.76 $19.01 −71% vs 086820

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Biosolution Co.Ltd · Fair Value
653.28 KRW −88%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Biosolution Co.Ltd Fair Value". https://www.fairvalue-calculator.com/stock/086820

Frequently asked questions

Is Biosolution Co.Ltd (086820) overvalued or undervalued?
As of Oct 28, 2026, our model estimates a fair value of 653.28 KRW versus a price of 5,590 KRW, about −88% upside (overvalued).
What is the fair value of 086820?
Our model-based fair value for Biosolution Co.Ltd is 653.28 KRW (as of Oct 28, 2026), built from audited fundamentals. The current price: 5,590 KRW.
What is the quality score of 086820?
Biosolution Co.Ltd has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Biosolution Co.Ltd (086820)?
Our model-based price target is the fair value of 653.28 KRW (as of Oct 28, 2026) from 10 valuation models. Cautious scenario 545.08 KRW, optimistic scenario 653.28 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Biosolution Co.Ltd stock forecast for 2026?
Our models put fair value at 653.28 KRW, about −88% upside versus a price of 5,590 KRW (overvalued). Cautious scenario 545.08 KRW, optimistic scenario 653.28 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Biosolution Co.Ltd (086820)?
Biosolution Co.Ltd reported trailing-twelve-month revenue of about 17.4B KRW (latest available figure, as of Oct 28, 2026).
What is the intrinsic value of Biosolution Co.Ltd (086820)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Biosolution Co.Ltd it is 653.28 KRW per share (as of Oct 28, 2026), against a price of 5,590 KRW. It is the blended result of 10 valuation models (cash flow, earnings, asset, dividend).
Is Biosolution Co.Ltd stock overvalued or undervalued in 2026?
As of Oct 28, 2026, 086820 trades above its calculated fair value: price 5,590 KRW, fair value 653.28 KRW, a gap of about −88% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 086820?
No. The price is what the market pays today (5,590 KRW); the fair value is what the company's own numbers justify (653.28 KRW). For Biosolution Co.Ltd the two are 4,937 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Biosolution Co.Ltd worth?
The market values Biosolution Co.Ltd at about 144B KRW (market capitalisation, as of Oct 28, 2026). Per share that is 5,590 KRW; our models calculate a fair value of 653.28 KRW per share.
What do the bullish and bearish scenarios say about 086820?
Our models span a range for Biosolution Co.Ltd: cautious scenario 545.08 KRW, base 653.28 KRW, optimistic 653.28 KRW per share (as of Oct 28, 2026, price 5,590 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Biosolution Co.Ltd (086820)?
Balance-sheet figures for Biosolution Co.Ltd (as of Oct 28, 2026): return on equity 2.5%. They feed the Quality Score of 50/100, which measures business quality independently of the share price.
How far is 086820 from its 52-week high?
Biosolution Co.Ltd trades at 5,590 KRW, about 57% below its 52-week high of 12,950 KRW and 1% above the low of 5,510 KRW (as of Oct 28, 2026). Distance from the high says nothing about value: that is what the fair value of 653.28 KRW is for.
Which stocks are comparable to Biosolution Co.Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Biosolution Co.Ltd stock attractive at the current price?
The data as of Oct 28, 2026: price 5,590 KRW, calculated fair value 653.28 KRW (−88%), Quality Score 50/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 086820 calculated?
We run Biosolution Co.Ltd through 10 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 653.28 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.4 % above its aggregate fair value. Biosolution Co.Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Biosolution Co.Ltd (086820)?
The closing price on Oct 28, 2026 was 5,590 KRW. Our model-based fair value is 653.28 KRW, about −88% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Biosolution Co.Ltd right now?
The price sits above even our optimistic bull case (653.28 KRW). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (50/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Biosolution Co.Ltd

How large is the market capitalisation of Biosolution Co.Ltd (086820)?
The market capitalisation of Biosolution Co.Ltd is 144B KRW (≈ $108M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Biosolution Co.Ltd (086820)?
The price-to-sales ratio of Biosolution Co.Ltd is 9.94 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Biosolution Co.Ltd (086820)?
The net margin of Biosolution Co.Ltd is 5.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Biosolution Co.Ltd (086820)?
The return on equity (ROE) of Biosolution Co.Ltd is 2.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Biosolution Co.Ltd (086820)?
On an EBIT basis the return on assets of Biosolution Co.Ltd is −6.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Biosolution Co.Ltd (086820)?
The operating margin of Biosolution Co.Ltd is −10.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Biosolution Co.Ltd (086820)?
Revenue at Biosolution Co.Ltd is growing +50.1% versus a year earlier (3y avg +14.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Biosolution Co.Ltd (086820) generate?
The free cash flow of Biosolution Co.Ltd is −2.0B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Biosolution Co.Ltd (086820) carry?
The net debt of Biosolution Co.Ltd is 17.2B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Biosolution Co.Ltd in the live analysis

One click puts Biosolution Co.Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.